Podcasts about Hyperlipidemia

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.     Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) - NEJM 2.     Diabetes and Anemia – Diabetes Care 3.     Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials – Diabetes Care 4.     Cardiovascular and Kidney Outcomes and Mortality With Long- Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials – Diabetes Care 5.     Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes - NEJM   For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Best Practices for Management of Hyperlipidemia: A Focus on Guidelines and Patient Adherence Educational Objectives Examine best practices for optimizing medication adherence and treatment initiation in hypercholesterolemia management Explain patient education and counseling for managing hypercholesteremia Faculty: Joseph Saseen, PharmD, BCPS, BCACP, CLS Professor and Associate Dean for Clinical Affairs University of Colorado Anschutz Medical Campus Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora, Colorado   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Executive Director, Ambulatory Pharmacy Services Grady Health System Atlanta, Georgia Joseph Saseen, PharmD, BCPS, BCACP, CLS, has the following financial relationships with commercial interests to disclose: Other Support (Lipid Monitoring Committee): Amgen (VESALIUS and OCEAN(a))   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA, has the following financial relationships with commercial interests to disclose: Grant/Research Support: Novartis Consultant: Novartis, Regeneron   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-9999-25-069-H01-P. The activity is available for CE credit through March 31, 2026.   This activity is jointly provided by the University of Connecticut School of Pharmacy–Storrs and Pharmacy Times Continuing Education™, and is supported by an educational grant from Novartis Pharmaceuticals Corporation.   Please follow the link below to access this activity on PTCE and claim CE credit: www.pharmacytimes.org/hyperlipidemiapodcast

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Best Practices for Management of Hyperlipidemia: A Focus on Guidelines and Patient Adherence Educational Objectives Examine best practices for optimizing medication adherence and treatment initiation in hypercholesterolemia management Explain patient education and counseling for managing hypercholesteremia Faculty: Joseph Saseen, PharmD, BCPS, BCACP, CLS Professor and Associate Dean for Clinical Affairs University of Colorado Anschutz Medical Campus Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora, Colorado   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Executive Director, Ambulatory Pharmacy Services Grady Health System Atlanta, Georgia Joseph Saseen, PharmD, BCPS, BCACP, CLS, has the following financial relationships with commercial interests to disclose: Other Support (Lipid Monitoring Committee): Amgen (VESALIUS and OCEAN(a))   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA, has the following financial relationships with commercial interests to disclose: Grant/Research Support: Novartis Consultant: Novartis, Regeneron   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-9999-25-069-H01-P. The activity is available for CE credit through March 31, 2026.   This activity is jointly provided by the University of Connecticut School of Pharmacy–Storrs and Pharmacy Times Continuing Education™, and is supported by an educational grant from Novartis Pharmaceuticals Corporation.   Please follow the link below to access this activity on PTCE and claim CE credit: www.pharmacytimes.org/hyperlipidemiapodcast

In today's episode, we are happy to hear from our clinic's Dr. Scott and one of his patients, Keith about his successful experience tackling gut health issues. Keith's case posed a very common conundrum that we've seen in many with gut health issues - are we dealing with bacterial overgrowth (SIBO), fungal overgrowth (candida) or potentially both? We'll walk through some of the key indications that Keith's initial SIBO diagnosis was actually a candida case, and we'll cover the best testing and treatments that led to Keith's recovery.  Need help navigating your digestive or other health conditions? Learn more about our virtual clinic: https://drruscio.com/virtual-clinic/

Stephanie Seneff introduces Deutenomics, a groundbreaking field reshaping our understanding of biology and medicine. Discover how this revolutionary science could transform health and disease management. #Deutenomics #BiologyRevolution #MedicalInnovation

Five articles from the January 2025 issue summarized in five minutes, with the addition of a brief editorial commentary. The 5-in-5 feature is designed to give readers an overview of articles that may pique their interest and encourage more detailed reading. It may also be used by busy readers who would prefer a brief audio summary in order to select the articles they want to read in full. The featured articles for this month are, “Posterolateral Knee Ligament Reconstruction Using the Arciero Technique Provides Greater Rotational Stability Than the Modified Larson Technique: A Biomechanical Study,” “Association Between Insufficient Restoration of Meniscal Tension During Surgical Repair of Medial Meniscus Root Tear and Surgical Outcomes: Clinical Implication of Curtain-Cliff Sign,” “Recovery of the Medial Elbow Joint in the 24-Hour Period After Repetitive Pitching in High School Players,” “Long-term Clinical and Structural Outcomes of Arthroscopic Superior Capsule Reconstruction for Irreparable Rotator Cuff Tears: 10-Year Follow-up,” and “Ezetimibe/Atorvastatin, a Treatment for Hyperlipidemia, Inhibits Supraspinatus Fatty Infiltration and Improves Bone-Tendon Interface Healing in a Rotator Cuff Tear Rat Model.” Click here to read the articles.

Welcome back to our weekend Cabral HouseCall shows! This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track! Check out today's questions:  Amy: Hi Dr. Cabral. First, thank you for all you do for the health community! You are my most trusted source of information. I'd love to get your thoughts on a red patch under my right eye. I've suffered through it flaring up and going away over half of this year. My dermatologist has tried 2 creams and we recently did a skin allergy test. While this was helpful, nothing has made it actually get better. I have a sneaking suspicion that it is more gut related than contact allergen related. Do you have any thoughts on ways to go about finding this root cause? Thanks!   Melissa: Hi! I just moved out of state and am in my mid 40s with menstrual irregularities. I'm feeling overwhelmed trying to find a new primary care and OBGYN that practices holistically with functional medicine therapies. How does one go about finding one. Or should I opt to doing a hormone therapy specialist?   Anonymous: Hi Dr. C, For several mornings now Ive been having a weird, somewhat sour chemical taste in my mouth. I believe this is due to my chronic constipation as my morning bowel movements are often incomplete, and any subsequent movements I have after my first one will smell more strongly of this sour chemical taste I wake up with in my mouth. My urine will have this smell as well. It does not smell of feces, just sort of chemically. I also have lots of pain in the area right below the sternum and seems to be chronic, and only reduces with the more bowel movements I have. Im already taking many magnesium supplements, motility activators, tudca, and miralax but I still find myself in these situations quite often. My stomach will often make high pitch, squealing sounds as if its straining   Lynne: Hello and thank you so much for all you do for all of us! I'm trying to understand why I tend to get benign growths such as lipomas. I also have a lump on my breast that has been there since I was 20. I am 52 and have gone through menopause and thought it would dissipate after the estrogen level dropped so dramatically. I also had hyperparathyroidism...another growth. Finally, I have a lymph node that feels like a tiny hard nodule on my neck (at the top near the ear). I have been taking proteolytic enzymes, am not overweight, exercise daily and eat a very clean diet. I would greatly appreciate any advice. Thank you!  Sorry, I forgot to mention that I listened to previous HouseCalls and have tried all of those things: massage, rebounder, sauna, dry brushing, castor oil, detoxes, etc. I have been doing these for a number of years.    Jill: Thanks for sharing your expertise and experience. I have a history of hyperlipidemia but through diet & lifestyle efforts have kept my cholesterol levels in check. Within the last few years, the levels have begun to climb and some of my inflammatory markers are worrisome. I am 53, post menopausal, and live an active lifestyle. I would like to avoid statins; however, I have been taking Icosapent Ethyl and Ezetimibe for the past 6 months and have seen a lowering of both my triglycerides and cholesterol to normal ranges again. My APOB is 139, LpA is 102 but my CT cardiac score is a zero. Where do I go from here? Is there any other testing I should consider to understand if need to continue on these medications, such as a CT angiogram?     Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions!    - - - Show Notes and Resources: StephenCabral.com/3263 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

21st H&H Academy Session

21st H&H Academy Session

With over 300 million people worldwide battling some sort of thyroid dysfunction, it's safe to say that it's one of the more common health issues. While most people think that stubborn weight loss or always feeling cold are the only signs of hypothyroidism, there are a few more that might surprise you. In this episode, I'm getting science-y and talking all about: - how your thyroid influences your body's metabolism - the difference between primary and subclinical hypothyroidism - the 10 unexpected signs you should be on the lookout for ... and more! --- Show Notes: References: Coursework from University of Western States Master's of Human Nutrition & Functional Medicine Association of Low Thyroid Hormone with Migraine Headache Psychiatric and cognitive manifestations of hypothyroidism Hypothyroidism and Depression: A Narrative Review Link between hypothyroidism and small intestinal bacterial overgrowth Radionuclide Esophageal Transit Scintigraphy in Primary Hypothyroidism Thyroid function and human reproductive health The role of thyroid function in female and male infertility: a narrative review Thyroid hormones and skeletal muscle — new insights and potential implications Hyperlipidemia and hypothyroidism Thyroid hormones: a potential ally to LDL-cholesterol-lowering agents --- 87: All About Your Thyroid // Hypothyroidism, Hashimoto's, Grave's Disease, & More Sign up for a 1:1 Discovery Call Join the Compass Method DIY Program Jump inside my Rock the Bloat Minicourse Get my Core-Gi Workout Program with the exclusive listener discount! Join my Brain Rewiring Masterclass You can learn more about me by following on IG @imperfectlypaigewellness or by checking out my blog, freebies, and offers on my website: https://imperfectlypaigewellness.com Please share with #PaigeTalksWellness to help get the word out about the show - and join the Imperfect Health Fam over on Facebook.

Intro of H&H Academy for non-physician healthcare providers

H&H Academy for non-physician healthcare providers

H&H Academy for non-physician healthcare providers

In this episode of The Nutritional Therapy and Wellness Podcast, host Jamie Belz and guest Amanda Jones dive into the fascinating science of blood sugar regulation and how its imbalance impacts the body. They explore how prediabetes and type II diabetes—like many chronic diseases—can often be reversed through strategic diet and lifestyle changes. Discover how achieving balanced blood sugar not only improves energy and vitality but also reduces or eliminates many associated health risks altogether. Amanda Jones is a dedicated instructor with the Nutritional Therapy Association (NTA) and an experienced Functional Nutritional Therapy Practitioner since 2013. In addition to being an FNTP, Amanda holds a master's degree in Human Nutrition and Functional Medicine, a bachelors degree in communications, she's a certified ADAPT Functional Health Coach, a certified GAPS Practitioner and a licensed massage therapist. 2:55 Diabetes, pre-diabetes, insulin - Blood Sugar 101 4:00 Why blood sugar regulation matters 4:45 Blood sugar regulation impacts everything in the entire body - nothing is NOT impacted 5:20 Current statistics for the prevalence of diabetes and pre-diabetes 6:50 Subclinical blood dysregulation - insulin resistance (PRE-PRE-DIABETES) 7:50 Reversing the pathway toward diabetes 10:45 How blood sugar dysregulation impacts the cardiovascular system - cardio-metabolic disease 11:50 Atherosclerosis as a result of blood sugar dysregulation 13:54 Glucose conversion to body fat 14:22 Blood lipids - triglycerides - hyperlipidemia 14:37 Why SUGAR is contributing to obesity rather than fats - as well as circulating lipids - 15:33 How elevated blood sugar drives elevated blood pressure and high blood pressure 16:20 How high insulin levels inhibit the production of nitric oxide levels 18:00 Immune regulation and meta-inflammation - inflammation driven by metabolic problems 19:30 Endocrine disruption from blood sugar dysregulation 21:10 Changes to the nervous system, gut motility, our microbiome, and other things negatively impacted by blood sugar dysregulation 21:40 The stages of dysglycemia 22:37 Insulin is a GOOD hormone! - What it's supposed to do in the body - how it brings sugar into the cells - how energy is produced 24:33 Excess glucose and insulin - reactive hypoglycemia 25:00 The Blood Sugar Rollercoaster - why you're tired at 10:30 AM, 2:30 PM, 8:00 PM 27:02 Insulin resistance 28:12 Fasting Glucose Levels - lab testing - Fasting Insulin Levels 30:20 The progression continues - feeling lethargic, gaining weight, etc. 30:30 Pre-Diabetes diagnosis 31:00 A1C - glycation 31:41 Metabolic Syndrome 32:40 Pancreas damage - insulin injections 33:04 Six small meals per day versus fasting 37:30 Fasting and time-restricted eating 38:09 Our blood sugar is synced with our circadian rhythms 39:58 Walking after meals versus other workouts for blood sugar regulation 41:46 There is HOPE! This doesn't need to be a miserable process. YOU can do it and you can enjoy it! ______________________ Catch Episode 29 to learn quick tips for improving blood sugar regulation for optimal health. Hit Subscribe! Connect with us at www.nutritionaltherapy.com

20th H&H Academy Session

20th H&H Academy Session

CardioNerds Cardio-Rheumatology Series Co-Chairs Dr. Rick Ferraro, Dr. Gurleen Kaur, and and Dr. Bree Hansen discuss how to decipher cardiovascular risk in patients with rheumatological conditions with cardio-rheumatology experts Dr. Brittany Weber and Dr. Michael Garshick. In this episode, Drs. Weber and Garshick take us through the role of inflammation in patients with rheumatologic conditions and cardiovascular disease. They discuss the increased prevalence of traditional cardiac risk factors in this population and how these standard cardiac risk factors do not account for the full extent of cardiovascular risk. Dr. Bree Hansen drafted show notes. Audio editing by CardioNerds intern Christiana Dangas. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - Cardio-Rheumatology - Deciphering Cardiovascular Risk in Patients with Rheumatological Conditions Cardiovascular disease prevalence: cardiovascular disease is common in patients with autoimmune rheumatologic disease; therefore, we must take every opportunity to screen patients early. Limitations of Traditional Scores: conventional risk calculators often underestimate cardiovascular risk for autoimmune disease patients, necessitating additional methods to assess risk accurately. Integration of Disease-Specific Biomarkers: using biomarkers specific to autoimmune diseases, such as lupus, enhances risk assessment and helps in tailoring treatment strategies. Value of Imaging and Risk Enhancers: incorporating imaging (like CAC scoring and carotid ultrasound) and evaluating additional risk factors (such as lipoprotein(a) and high-sensitivity CRP) provides a more comprehensive view of cardiovascular risk and guides more effective management. Show notes - Cardio-Rheumatology - Deciphering Cardiovascular Risk in Patients with Rheumatological Conditions Show notes (Drafted by Dr. Bree Hansen): How does inflammation contribute to atherosclerosis, specifically in autoimmune rheumatologic diseases like psoriasis? Lipids need to enter the intimal space of blood vessels, which can be facilitated by endothelial damage caused by chronic cytokine stimulation, such as TNF or IL-6. Once in the intima, lipids are recognized as foreign, leading to the recruitment of monocytes that transform into macrophages to clear these lipids. However, this process often exacerbates the problem, leading to persistent inflammation and atherosclerotic plaque formation. Specifically, in psoriasis, the endothelial damage is particularly pronounced due to cytokines like TNF, IL-17, and interferons. The inflammasome pathway, which is highly active in psoriasis, also contributes to endothelial damage. Additionally, hyperactivated platelets in psoriasis can further damage the endothelium and contribute to atherosclerosis. Overall, atherosclerosis results from a combination of traditional risk factors and systemic inflammation, leading to the development of cardiovascular disease. Which traditional cardiovascular risk factors are increased in patients with rheumatologic conditions? Patients with autoimmune diseases may be up to > three times more likely to develop cardiovascular disease, similar to the risk of type 2 diabetes; therefore, it is important to screen patients with autoimmune rheumatologic disorders for cardiovascular disease Most common cardiovascular risk factors, such as smoking, diabetes, hypertension, and dyslipidemia, are also increased in patients with autoimmune rheumatologic disorders. Smoking, specifically, is highly prevalent in psoriasis and exhibits a dose-response relationship with psoriasis severity. Hyperlipidemia is another common risk factor present in patients with autoimmune rheumatologic disease; however,

19th H&H Academy Session

19th H&H Academy Session

18th H&H Academy Session

18th H&H Academy Session

17th H&H Academy Session

17th H&H Academy Session

16th H&H Academy Session

16th H&H Academy Session

CME credits: 0.75 Valid until: 14-06-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-practice-guidelines-for-hyperlipidemia-what-are-the-recommendations/26263/ Explore the future of cholesterol management with cutting-edge pharmacologic therapies and the latest research on lipid-lowering treatments. Understand the transformative impact of AI in primary cardiovascular disease prevention, as highlighted by groundbreaking trials like TRANSFORM. Stay informed on how emerging therapies can help patients achieve optimal LDL-C levels and reduce cardiovascular risks.

Stephen Mcconnell is a scientist, researcher, and lipidemiologist. He is an expert in the use of Niacin, his work is international, and his protocols have been widely used by physicians. In this insightful episode, we dive deep into the often misunderstood world of niacin or vitamin B3, which has been unfairly vilified and blamed for increasing cardiovascular disease risk, but Stephen dispels these myths and misconceptions. We explore the actual benefits of niacin, including:Its role in lowering cholesterol and triglyceride levelsIts role in lowering Lp (a) and ApoBUse in treating certain conditions, like fatty liver disease and chronic kidney disease (CPK)Stephen provides guidance on who makes a good candidate for niacin supplementation and which conditions it may be particularly helpful for.  He also covers proper dosing protocols, how to take niacin safely and effectively, and tips for minimizing the infamous "niacin flush."Don't miss this eye-opening discussion that separates fact from fiction when it comes to this powerful vitamin. Tune in to learn how niacin could potentially improve your health from an expert who has studied it extensively!Prefer to watch the interview? Join my YouTube channel here:https://www.youtube.com/channel/UCP1MLJvcxegZ7Bv7---PUEQThank you for being here, enjoy the interview! In health,KimSupport the Show.Follow me:FacebookFacebook groupInstagramTwitterLinkedInPlease subscribe to my YouTube channel!

CME credits: 0.75 Valid until: 20-06-2025 Claim your CME credit at https://reachmd.com/programs/cme/plozasiran-aro-apoc3-decreases-apoc3-and-triglycerides-tg-in-patients-with-mixed-hyperlipidemia-muir-final-results/24409/ This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.

BUFFALO, NY- March 20, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 5, entitled, “FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet.” FoxO6, an identified factor, induces hyperlipidemia and hepatic steatosis during aging by activating hepatic lipoprotein secretion and lipogenesis leading to increased ApoC3 concentrations in the bloodstream. However, the intricate mechanisms underlying hepatic steatosis induced by elevated FoxO6 under hyperglycemic conditions remain intricate and require further elucidation. In this new study, researchers Dae Hyun Kim, Seulah Lee, Sang Gyun Noh, Jaewon Lee, and Hae Young Chung from Pusan National University aimed to delineate the regulatory pathway involving ApoC3 controlled by FoxO6 and its resultant functional impacts. “[...] we employed a spectrum of models including liver cell cultures, aged rats subjected to HFD, transgenic mice overexpressing FoxO6 (FoxO6-Tg), and FoxO6 knockout mice (FoxO6-KO).” Their findings indicate that FoxO6 triggered ApoC3-driven lipid accumulation in the livers of aged rats on an HFD and in FoxO6-Tg, consequently leading to hepatic steatosis and hyperglycemia. Conversely, the absence of FoxO6 attenuated the expression of genes involved in lipogenesis, resulting in diminished hepatic lipid accumulation and mitigated hyperlipidemia in murine models. Additionally, the upregulation of FoxO6 due to elevated glucose levels led to increased ApoC3 expression, consequently instigating cellular triglyceride mediated lipid accumulation. The transcriptional activation of FoxO6 induced by both the HFD and high glucose levels resulted in hepatic steatosis by upregulating ApoC3 and genes associated with gluconeogenesis in aged rats and liver cell cultures. “Our conclusions indicate that the upregulation of ApoC3 by FoxO6 promotes the development of hyperlipidemia, hyperglycemia, and hepatic steatosis in vivo, and in vitro. Taken together, our findings underscore the significance of FoxO6 in driving hyperlipidemia and hepatic steatosis specifically under hyperglycemic states by enhancing the expression of ApoC3 in aged rats.” DOI - https://doi.org/10.18632/aging.205610 Corresponding author - Hae Young Chung - hyjung@pusan.ac.kr Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205610 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, HFD-feeding aging, forkhead transcription factor O6, ApoC3, lipid accumulation, hepatic steatosis Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer's diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases. Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GVK865. CME credit will be available until February 13, 2025.Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia ManagementThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.DisclosuresR. Scott Wright, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Novo Nordisk Inc.CME ReviewerRamil GoelAssistant Professor of MedicineDivision of Cardiovascular MedicineElectrophysiology SectionUniversity of Florida College of MedicineGainesville, FloridaRamil Goel, MD, FHRS, has no relevant financial relationships to disclose.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GVK865. CME credit will be available until February 13, 2025.Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia ManagementThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.DisclosuresR. Scott Wright, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Novo Nordisk Inc.CME ReviewerRamil GoelAssistant Professor of MedicineDivision of Cardiovascular MedicineElectrophysiology SectionUniversity of Florida College of MedicineGainesville, FloridaRamil Goel, MD, FHRS, has no relevant financial relationships to disclose.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GVK865. CME credit will be available until February 13, 2025.Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia ManagementThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.DisclosuresR. Scott Wright, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Novo Nordisk Inc.CME ReviewerRamil GoelAssistant Professor of MedicineDivision of Cardiovascular MedicineElectrophysiology SectionUniversity of Florida College of MedicineGainesville, FloridaRamil Goel, MD, FHRS, has no relevant financial relationships to disclose.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GVK865. CME credit will be available until February 13, 2025.Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia ManagementThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.DisclosuresR. Scott Wright, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Novo Nordisk Inc.CME ReviewerRamil GoelAssistant Professor of MedicineDivision of Cardiovascular MedicineElectrophysiology SectionUniversity of Florida College of MedicineGainesville, FloridaRamil Goel, MD, FHRS, has no relevant financial relationships to disclose.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GVK865. CME credit will be available until February 13, 2025.Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia ManagementThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.DisclosuresR. Scott Wright, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Novo Nordisk Inc.CME ReviewerRamil GoelAssistant Professor of MedicineDivision of Cardiovascular MedicineElectrophysiology SectionUniversity of Florida College of MedicineGainesville, FloridaRamil Goel, MD, FHRS, has no relevant financial relationships to disclose.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GVK865. CME credit will be available until February 13, 2025.Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia ManagementThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.DisclosuresR. Scott Wright, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Novo Nordisk Inc.CME ReviewerRamil GoelAssistant Professor of MedicineDivision of Cardiovascular MedicineElectrophysiology SectionUniversity of Florida College of MedicineGainesville, FloridaRamil Goel, MD, FHRS, has no relevant financial relationships to disclose.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GVK865. CME credit will be available until February 13, 2025.Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia ManagementThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.DisclosuresR. Scott Wright, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Novo Nordisk Inc.CME ReviewerRamil GoelAssistant Professor of MedicineDivision of Cardiovascular MedicineElectrophysiology SectionUniversity of Florida College of MedicineGainesville, FloridaRamil Goel, MD, FHRS, has no relevant financial relationships to disclose.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GVK865. CME credit will be available until February 13, 2025.Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia ManagementThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.DisclosuresR. Scott Wright, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Novo Nordisk Inc.CME ReviewerRamil GoelAssistant Professor of MedicineDivision of Cardiovascular MedicineElectrophysiology SectionUniversity of Florida College of MedicineGainesville, FloridaRamil Goel, MD, FHRS, has no relevant financial relationships to disclose.

Highlights of the JAANP issue topics: Antibiotic Stewardship, Transgender Healthcare, Diabetes, Hyperlipidemia, Persons with Disabilities, microcurrent neurofeedback,

15th H&H Academy

15th H&H Academy

14th H&H Academy

14th H&H Academy

Obesity Canada published a guideline in 2020 that we will be referring to a lot in this episode. It defines obesity as a chronic, progressive and relapsing disease characterized by the presence of adiposity that impairs health and social well-being.    So today you'll learn what you need to know for the exam, but also some practical considerations for real life visits that take into account the pressures of diet culture, and how we as physicians can provide evidence based advice that doesn't isolate and judge our patients. And because we know language matters, you'll hear us use terms like “large bodies”, instead of saying someone is fat. There are advocates who have reclaimed the term fat, but today we'll stick with medical jargon and terms aimed to avoid stigma.  

During the 2023 American Association for the Study of Liver Diseases conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-δ agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Kris V. Kowdley MD, FAASLD, FACP, FACG, discusses topline results from several of these studies and more, including: A combination of 3 studies—HEROES, COBALT, and COBALT EC—that evaluated the real-world effectiveness and safety of second-line therapy in PBC where OCA was added to the treatment regimen of people with PBC with an incomplete response to ursodeoxycholic acid Lessons learned from a long-term outcomes study of people with PBCResults from 2 phase II studies of obeticholic acid plus bezafibrate in people with PBC who did not respond to or were intolerant of ursodeoxycholic acidPresenter:Kris V. Kowdley MD, FAASLD, FACP, FACGProfessor, Elson S. Floyd College of MedicineWashington State UniversityDirector, Liver Institute NorthwestSeattle, Washington      Link to reviews of other PBC studies from AASLD 2023: https://bit.ly/3RvXXEI

During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Stuart C. Gordon, MD, FAASLD, discusses topline results from one of these late-breaking studies and more, including: A phase III study of an investigational PPAR-delta agonist (seladelpar) in people with PBC who had failed to respond to ursodeoxycholic acidA study that explored racial differences as they relate to the presentation and diagnosis of PBCPresenter: Stuart C. Gordon, MD, FAASLDDirector of HepatologyHenry Ford Health SystemProfessor of MedicineWayne State University School of MedicineDetroit, MichiganLink to commentary:https://bit.ly/3GzRMt2Link to reviews of other PBC studies from AASLD 2023:https://bit.ly/3RvXXEI

During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Marlyn J. Mayo, MD, discusses topline results from several of these studies and more, including: A phase III study of an investigational dual PPAR α/δ agonist (elafibranor) in people with PBC who did not respond to or were intolerant of ursodeoxycholic acid (UDCA)A study that evaluated the effectiveness and safety of second-line therapy in PBC where obeticholic acid with or without a fibrate was added to the treatment regimen of people with PBC with an incomplete response to UDCAA retrospective review of the rates of hyperlipidemia, atherosclerosis, and/or hepatic steatosis in patients with PBCPresenter: Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasLink to commentary:https://bit.ly/47PmGdcLink to reviews of other PBC studies from AASLD 2023: https://bit.ly/3RvXXEI

H&H Academy session

H&H Academy session

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Hypercholersterolemia / Hyperlipidemia ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Cardiovascular section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-332 Overview: In this episode, we take a look at the dynamic landscape of hyperlipidemia management, discussing current guidelines for hyperlipidemia treatment and the interplay between evidence-based recommendations and expert opinions. Tune in to gain a broader understanding of hyperlipidemia management and unlock fresh perspectives to enhance patient care. Episode resource links: JAMA Intern Med. March 14, 2022. doi:10.1001/jamainternmed.2022.0134 JAMA. Published online March 6, 2023. doi:10.1001/jama.2023.2487 Guest: Robert A. Baldor MD, FAAFP   Music Credit: Richard Onorato